Picture of NeuroPace logo

NPCE — NeuroPace News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Neuropace Inc expected to post a loss of 46 cents a share - Earnings Preview

* Neuropace Inc  NPCE.OQ   NPCE.O  is expected to show a
rise in
quarterly revenue when it reports  results on May 4. 
    * The Mountain View California-based  company is expected to
report  a 7.0% increase in revenue to $12.168 million from
$11.37 million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Neuropace Inc is
for a
loss of 46 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.3%
in the last three months. ​
    * Wall Street's median 12-month price target for Neuropace
Inc is
$6​, above​ its last closing price of $4.94. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.50       -0.49      -0.45     Beat    9.1
 Sep. 30 2022  -0.52       -0.53      -0.48     Beat    8.9
 Jun. 30 2022  -0.44       -0.44      -0.52     Missed  -17.3​
 Mar. 31 2022  -0.45       -0.44      -0.47     Missed  -6.2
 ​​Dec.        -0.32       -0.33      -0.44     Missed  -33.3
 31 2021                                                
 Sep. 30 2021  -0.31       -0.30      -0.34     Missed  -11.8​
 Jun. 30 2021  -0.34       -0.34      -0.48     Missed  -42.6
 Mar. 31 2021  -0.28       -0.28      -32.73    Missed  -11,58
                                                        9.3
 This summary was machine generated May 3 at 02:08 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on NeuroPace

See all news